#India #Waltham #AI Imaging #LungVision #Body Vision Medical

Body Vision Medical Expands Lung Cancer Diagnostic Capabilities in India

Body Vision Medical, a frontrunner in AI-enhanced intraoperative imaging solutions, recently achieved a significant milestone by obtaining regulatory approval for its advanced imaging system, LungVision, in India. The approval was granted by the Central Drugs Standard Control Organization (CDSCO), marking a major step forward in the fight against lung cancer in a country with pressing needs for effective diagnostic tools.

Lung cancer is a critical public health issue in India, accounting for 8.1% of cancer-related deaths. According to projections from the National Cancer Registry Programme (NCRP) and the GLOBOCAN project, an estimated 111,328 new lung cancer cases are expected to be diagnosed in 2025. Alarmingly, late-stage diagnoses—where 75% of cases are identified at stages three and four—lead to a stark five-year survival rate of only around 15%. This stands in stark contrast to survival rates of approximately 45% in more developed nations, highlighting the urgent need for early detection and diagnosis in India.

Matt Baker, CEO of Body Vision Medical, stated, "Obtaining approval in India represents a pivotal advancement in our global mission to revolutionize lung cancer care. We are eager to collaborate with Assiz Sarah Healthcare to introduce LungVision where the demand for early detection of suspicious pulmonary nodules is critical."

LungVision utilizes state-of-the-art AI technology to transform any C-arm used in medical practices into a sophisticated 3D imaging system. This innovative tool empowers healthcare professionals by providing real-time navigation and enhanced visualization during bronchoscopic procedures. Such capabilities ensure that biopsies are conducted more accurately and efficiently, significantly boosting diagnostic confidence.

In conjunction with the clinical objectives outlined in the National Lung Cancer Screening Program (NLCSP), LungVision promotes timely and decisive diagnosis, ultimately paving the way to improved outcomes for patients. Ravinder Saini, Director of Assiz Sarah Healthcare, expressed enthusiasm about the partnership, stating that Body Vision's technology aligns with their commitment to progress in lung and respiratory medicine through cutting-edge AI solutions. "Integrating Body Vision's real-time imaging technology into our offerings opens up remarkable possibilities for early cancer detection, which is critical to enhancing survival rates," he added.

With LungVision set to be made available through Assiz Sarah Healthcare, patients in India can expect improved access to advanced diagnostic tools that can change the trajectory of lung cancer care. This strategic partnership aims to bridge the gap in healthcare provisions for lung cancer, which is increasingly recognized as a major public health concern.

To learn more about LungVision and its availability in India, interested parties are encouraged to visit the Assiz Sarah Healthcare website at assizsarah.com.

About Body Vision Medical

Body Vision Medical is dedicated to saving lives through the globalization of innovative medical technologies. Its LungVision system offers AI-based real-time image guidance, addressing the urgent clinical requirement for early and definitive lung cancer diagnoses, and facilitating the effective treatment of lung lesions through minimally invasive methods. For further details, visit bodyvisionmedical.com and connect via LinkedIn.

About Assiz Sarah Healthcare

Assiz Sarah Healthcare is committed to revolutionizing healthcare experiences through strategic partnerships and innovative technologies. The organization is focused on enhancing healthcare provision through compassionate care, ensuring access to advanced solutions vital for a healthier future.